GHRH will be assessed as a potential treatment to combat wasting associated with HIV and cancer.

VGX Pharmaceuticals signed a license agreement with Baylor College of Medicine covering a broad range of Growth Hormone Releasing Hormone (GHRH) technology and related intellectual property for application in humans.

VGX thus gains exclusive, worldwide rights to develop the technology for a number of indications, including cachexia in cancer and HIV patients as well as age-related disorders. This agreement broadens the existing relationship between the two organizations.

“The licensed technology will augment our growing early-stage pipeline of DNA-based therapeutics and vaccines being developed at the VGX-immune therapeutics division,” points out J. Joseph Kim, president and CEO of VGX Pharmaceuticals.

“We already have on-going programs in both HIV and cancer, and the development of GHRH as a potential treatment to combat wasting associated with these diseases may represent an important step in the management of these diseases. Our early efficacy data on the use of plasmid-mediated GHRH supplementation for alleviating cancer-cachexia in dogs has proved to be very promising, and this licensing agreement allows us access to further develop the technology for human applications.”

Previous articleStallergenes and CMC Biopharmaceuticals Collaborate to Advance Allergy Drug
Next articleBio-Matrix Takes Step toward Setting Up Adipose Tissue-Derived Stem Cell Bank